BEBT-305
BEBT-305 is the world's first second-generation orally administered HSP90 inhibitor for the treatment of psoriasis and other autoimmune diseases. Preclinical and clinical research results have demonstrated favorable pharmacological characteristics for psoriasis treatment. These include strong oral bioavailability, potent HSP90 inhibition, suppression of multiple inflammatory factors, high skin exposure, and a good safety profile. As the world's first second-generation orally administered HSP90 inhibitor for the treatment of psoriasis and other autoimmune diseases, the company's BEBT-305 is currently in Phase I clinical trials for the treatment of severe plaque psoriasis. Additionally, BEBT-305 received approval from CDE in March 2023 to conduct Phase Ib clinical trials for moderate to severe hidradenitis suppurativa.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号